Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib + TAS-102 for second-line advanced gastric cancer
ChiCTR2300072664Phase 2Recruiting
- Sponsor
- Xiamen University Affiliated Zhongshan Hospital
- Start
- Jun 2023
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib and trifluridine + tipiracil in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Xiamen University Affiliated Zhongshan Hospital. Primary endpoint: objective response rate. Started Jun 2023; status: recruiting.
02
Drugs
Rivoceranibtrifluridine + tipiracil
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2300072664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300072664.